AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21619670
Drug: Dabbas dates
RxNorm normalized name: Date
DrugBank: Date (DB10632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabbas dates (50 g equivalent of available carbohydrates)
Trial: 21619670
Drug: Khalas dates
RxNorm normalized name: Date
DrugBank: Date (DB10632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Khalas dates (50 g equivalent of available carbohydrates)
Trial: 21619670
Drug: Fara'd dates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fara'd dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Trial: 21619670
Drug: Lulu dates
RxNorm normalized name: Date
DrugBank: Date (DB10632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lulu dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Trial: 21619670
Drug: Bo ma'an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bo ma'an dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Trial: 21619670
Drug: Dabbas dates
RxNorm normalized name: Date
DrugBank: Date (DB10632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabbas dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Trial: 21619670
Drug: Khalas dates
RxNorm normalized name: Date
DrugBank: Date (DB10632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Khalas dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Trial: 21619692
Drug: Brazil nuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazil nuts (BNG), n = 8, 15-25 g/day (equivalent to 3 to 5 units/day)
Trial: 21619692
Drug: Placebo (PG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PG, lactose), n = 9, one capsule/day
Trial: 21622693
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa (150 µg)
Trial: 21623265
Drug: Crizotinib (PF02341066),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib (PF02341066), a dual MET and ALK inhibitor; specific dosage and duration not mentioned.
Trial: 21623649
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B12 (9 μg daily)
Trial: 21627839
Drug: Carboplatin plus
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin plus celecoxib (400 mg/day)
Trial: 21628633
Drug: Phylloquinone supplementation
RxNorm normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phylloquinone supplementation (500 μg/d) for 3 years
Trial: 21632855
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy 30 days before tumor harvest
Trial: 21633906
Drug: Bortezomib (a
RxNorm normalized name: bortezomib (as mannitol boronic ester)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (a 26S proteasome inhibitor)
Trial: 21635145
Drug: Prednisolone treatment
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone treatment in healthy volunteers
Trial: 21639407
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OM) 20 mg, uptitrated to OM 40 mg, followed by hydrochlorothiazide (HCTZ) 12.5-25 mg at 3-week intervals
Trial: 21642245
Drug: Adenoviral vector
RxNorm normalized name: Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12
DrugBank: Ad-RTS-hIL-12 (DB17177)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenoviral vector encoding human IFN-α (Ad.IFN-α2b) administered intrapleurally, two doses.
Trial: 21642514
Drug: Neoadjuvant trabectedin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant trabectedin (1.5 mg/m(2) 24-h i.v. infusion every 3 weeks; three to six cycles)
Trial: 21642685
Drug: Imatinib mesylate,
RxNorm normalized name: Imatinib Mesylate, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib mesylate, 400 mg orally twice daily
Trial: 21646032
Drug: Sapropterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sapropterin dihydrochloride (Kuvan®) at a mean dose of 16.2±4.7 mg/kg/day for an average exposure of 658.7±221.3 days.
Trial: 21648284
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) stimulation testing with arginine and GH releasing hormone
Trial: 21649541
Drug: Enzastaurin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin (250 mg twice daily)
Trial: 21653689
Drug: Erlotinib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (125 mg/m²/day for children, 90 mg/m²/day for adults)
Trial: 21657861
Drug: Subcutaneous methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous methylnaltrexone (0.15 mg/kg initial dose, adjusted to 0.3 mg/kg or 0.075 mg/kg as needed, maximum one dose per 24 hours)
Trial: 21659356
Drug: Treosulfan (3×14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treosulfan (3×14 g/m²) and Fludarabine (5×30 mg/m²)
Trial: 21659363
Drug: Decitabine 20
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 20 mg/m(2)/day intravenously over one hour for five consecutive days every four weeks
Trial: 31375393
Drug: Decitabine treatment
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine treatment
Trial: 21663862
Drug: Weekly topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly topotecan (6 mg/m(2) I.V. for 6 weeks)
Trial: 21664608
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of drug use
Trial: 21666249
Drug: Kidney injury
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kidney injury molecule 1 (KIM-1)
Trial: 21666249
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of impaired eGFR, increased UACR, and high NAG
Trial: 21667134
Drug: Preoperative S-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative S-1 (80 mg/m²/day, days 1-21) plus cisplatin (60 mg/m² on day 8) for 2 courses followed by radical gastrectomy and postoperative S-1 (80 mg/m²/day, days 1-14) every 3 weeks for 1 year
Trial: 21668924
Drug: Dipeptidyl peptidase-4
RxNorm normalized name: Immature tripeptidyl-peptidase I
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dipeptidyl peptidase-4 inhibitor sitagliptin
Trial: 21670449
Drug: Imatinib 260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 260 mg/m² daily
Trial: 21673350
Drug: Epratuzumab (E)
RxNorm normalized name: Vitamin E
DrugBank: Epratuzumab (DB04958)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epratuzumab (E) 360 mg/m² intravenously with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for 6 cycles
Trial: 21674178
Drug: Hyperglycaemia (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (18 mmol/l)
Trial: 21674178
Drug: Hypoglycaemia (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia (2.5 mmol/l) followed by hyperglycaemia (12 mmol/l) and another hypoglycaemia (3.0 mmol/l)
Trial: 21675055
Drug: Erythropoietin (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (exact dosage and duration not specified)
Trial: 21676217
Drug: Lapatinib 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1250 mg/day continuously and capecitabine 1000 mg/m2 twice daily on a 2-week-on and 1-week-off schedule
Trial: 21676394
Drug: Ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl estradiol (35 μg) and norgestimate (0.18/0.215/0.25 mg) for 6 cycles
Trial: 21676694
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavior therapy (CBT)
Trial: 21679735
Drug: Autologous dendritic-cell-based
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dendritic-cell-based therapeutic HIV-1 vaccine
Trial: 21680850
Drug: Aliskiren (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (oral direct renin inhibitor) for 12 months
Trial: 21681115
Drug: 72-hour coefficient
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 128 mg in 1 mL TOPICAL CREAM [Kiehls Since 1851 Superbly Efficient Antiperspirant and Deodorant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72-hour coefficient of fat absorption (CFA) measurement
Trial: 21685540
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg EFV with RFN
Trial: 21685540
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg EFV with RFN
Trial: 21686825
Drug: Orthopaedic full
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthopaedic full spinal supports along with conventional treatment
Trial: 21690557
Drug: Pomalidomide 2
RxNorm normalized name: pomalidomide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 2 mg/d with dexamethasone 40 mg weekly
Trial: 21690557
Drug: Pomalidomide 4
RxNorm normalized name: pomalidomide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4 mg/d with dexamethasone 40 mg weekly
Trial: 21692673
Drug: Vaccination, antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination, antiviral strategies, and infection control measures
Trial: 21692673
Drug: Antiviral therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapies
Trial: 21692906
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin (SCIG) therapy
Trial: 21693599
Drug: Activation of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activation of compound patterns (simplified letters)
Trial: 21693599
Drug: Concurrent retinal
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent retinal stimulation
Trial: 21696575
Drug: Vitamin D3-fortified
RxNorm normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3-fortified yogurt drink (FYD; 500 IU vitamin D/250 mL)
Trial: 21697252
Drug: Lanreotide acetate
RxNorm normalized name: Lanreotide Acetate
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanreotide acetate (Somatuline Autogel), 30 mg once a month, administered by deep subcutaneous injection.
Trial: 21697252
Drug: Octreotide via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide via insulin pump (initial treatment).
Trial: 21699130
Drug: Metronidazole gel
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole gel 1%
Trial: 21699369
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ezetimibe and 20 mg simvastatin once daily for 6 weeks
Trial: 21699798
Drug: TG4040 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG4040 vaccine (10⁶, 10⁷, or 10⁸ plaque-forming units) administered subcutaneously on days 1, 8, and 15.
Trial: 21699798
Drug: TG4040 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG4040 vaccine (10⁸ plaque-forming units) administered subcutaneously.
Trial: 21699798
Drug: TG4040 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG4040 vaccine (10⁸ plaque-forming units) with marked T-cell responses.
Trial: 21700776
Drug: Decitabine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (0.2 mg/kg subcutaneous 2 times per week for 12 weeks)
Trial: 21701566
Drug: Lowest two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest two quartiles of insulin sensitivity (S(I) <50th)
Trial: 21701566
Drug: Most insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Most insulin sensitive (IS) individuals
Trial: 21701566
Drug: Most insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Most insulin resistant (IR) individuals
Trial: 21701566
Drug: Highest two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest two quartiles of insulin sensitivity (S(I) >50th)
Trial: 21702914
Drug: Salvage docetaxel/cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage docetaxel/cisplatin chemotherapy
Trial: 21711530
Drug: Parental group
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental group support therapy, online/offline website, pediatrician involvement, video simulation game ('Dr. Cruz'), personalized biochemical feedback on exposure levels.
Trial: 21714878
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day ribavirin (group C) for 16 weeks
Trial: 21714878
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day ribavirin (group D) for 16 weeks
Trial: 21714878
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day ribavirin (group C) for 16 weeks with low viral load
Trial: 21714878
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day ribavirin (group D) for 16 weeks with low viral load
Trial: 21714878
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day ribavirin (group C) for 16 weeks with high viral load
Trial: 21714878
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day ribavirin (group D) for 16 weeks with high viral load
Trial: 21715509
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g yellow maize porridge containing 1.2 mg β-carotene, 20 g butter, and a 0.5-g corn oil capsule
Trial: 21715509
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg [(13)C(10)]retinyl acetate in a 0.5-g corn oil capsule and 300 g white maize porridge with 20 g butter
Trial: 21716260
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg paricalcitol, orally active vitamin D receptor activator, every morning for 7 days
Trial: 21717386
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (5 or 10 mg) daily for 12 months
Trial: 21719129
Drug: hsCRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP levels ≥2mg/L
Trial: 21719129
Drug: hsCRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP levels <2mg/L
Trial: 21719129
Drug: hsCRP, LDL-cholesterol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP, LDL-cholesterol, BMI, and insulin resistance
Trial: 21719884
Drug: Lenalidomide up
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide up to 30 mg daily for 16 weeks
Trial: 21721925
Drug: Acupuncture treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment, twice a week for 6 weeks
Trial: 21723591
Drug: Hemoglobin levels
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin levels below 14 g/dL
Trial: 21723591
Drug: Hemoglobin levels
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin levels at or above 14 g/dL
Trial: 21725050
Drug: Lenalidomide 5
RxNorm normalized name: lenalidomide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 5 mg daily for 56 days, then titrated up to 25 mg/d as tolerated
Trial: 21725050
Drug: Lenalidomide therapy
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide therapy
Trial: 21725056
Drug: Tipifarnib 300
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle
Trial: 21729182
Drug: Inhaled dust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dust mite allergen challenge (Dermatophagoides farinae extract; PD(max) = fall in forced expiratory volume in 1 s of 10%)
Trial: 21729182
Drug: Inhaled dust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dust mite allergen challenge
Trial: 21732212
Drug: Monthly self-weighing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly self-weighing
Trial: 21733227
Drug: OROS-MPH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS-MPH treatment for 12 weeks
Trial: 21738597
Drug: Five-drug combination
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug combination antiretroviral therapy (cART) including enfuvirtide for the first 6 months, optimized cART with three or more drugs for 12 months.
Trial: 21740082
Drug: Bortezomib in
RxNorm normalized name: bortezomib Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib in combination with arsenic trioxide, sorafenib, and cytarabine
Trial: 21740673
Drug: Empiric TB
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric TB treatment given to 8 (40%) patients
Trial: 21741058
Drug: Rosiglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone treatment for 8 weeks
Trial: 21742281
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) herbal concoctions taken orally for 24 weeks while continuing with Western medical management.
Trial: 21742281
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) herbal concoctions
Trial: 21744485
Drug: Hydroxyurea overdose
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea overdose (612 mg/kg body weight)
Trial: 21745716
Drug: Standard antimalarial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antimalarial therapy
Trial: 21748299
Drug: Figitumumab 20
RxNorm normalized name: Figitumumab
DrugBank: Figitumumab (DB11685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Figitumumab 20 mg/kg in combination with carboplatin and paclitaxel
Trial: 21748299
Drug: Figitumumab (6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin and paclitaxel
Trial: 21749641
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) treatment
Trial: 21749698
Drug: Mean dose
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean dose to whole breast
Trial: 21752435
Drug: Temsirolimus 25mg
RxNorm normalized name: TEMSIROLIMUS 25MG/ML INJ,SOLN
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 25mg weekly IV until progression or intolerable toxicity
Trial: 21752743
Drug: Diet, oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet, oral antidiabetes agents, and/or injectables (insulin and/or GLP-1 analogues)
Trial: 21752947
Drug: Vero cell
RxNorm normalized name: Vero Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vero cell antirabies vaccine
Trial: 21752947
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose after 5 years
Trial: 21756035
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m² days 1, 4, 8, 11, 45, 52), cyclophosphamide (50 mg/kg days 15-18), pegfilgrastim (day 20)
Trial: 21763217
Drug: Mood-stabilizing medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mood-stabilizing medications